Abstract
In the 2-year, phase 3 CARE-MS studies of alemtuzumab in patients with relapsing-remitting multiple sclerosis, infusion-associated reactions (IARs) were the most common adverse events. Here we report on IARs during...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have